ReviewHuman vaccines & immunotherapeutics2026
The 15-year bibliometric landscape of glioblastoma vaccines: Emergence of combinatorial immunotherapy.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the persistently poor prognosis of glioblastoma (GBM), research into novel immunotherapies, particularly tumor vaccines, has flourished, evolving into a highly active and interdisciplinary field. Through a bibliometric analysis of 1,096 relevant publications from 2010 to 2025, this study systematically maps the intellectual structure, collaborative networks, and thematic evolution of this domain. The analysis reveals a significant paradigm shift: the research focus has transitioned from early antigen-specific vaccine development toward the comprehensive modulation of the immunosuppressive tumor microenvironment. This shift is evidenced by in-depth investigations into combination immunotherapies (e.g., with immune checkpoint inhibitors), advanced delivery technologies designed to overcome the blood-brain barrier (such as focused ultrasound and biomimetic nanocarriers), and innovative platforms including oncolytic viruses and stem cell-based systems. Overall, over the past 15 y, the field has evolved from strategies centered on unilateral immune activation toward integrated, synergistic approaches aimed at counteracting systemic immunosuppression. Future breakthroughs are anticipated to depend on refining personalized neoantigen-targeting strategies and optimizing multimodal combination therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.